We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess the Transfer of Fospropofol and Its Active Metabolite, Propofol, to Breast Milk Following Administration of LUSEDRA to Lactating Women Undergoing a Needed Procedure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01309984
Recruitment Status : Completed
First Posted : March 7, 2011
Last Update Posted : November 3, 2015
Sponsor:
Information provided by (Responsible Party):

March 2, 2011
March 7, 2011
November 3, 2015
November 2010
October 2012   (Final data collection date for primary outcome measure)
  • Total amount (Ae0-24) of propofol transferred to breast milk in 24 hours. [ Time Frame: 24 hours ]
  • Total amount (Ae0-24) of fospropofol transferred to breast milk in 24 hours [ Time Frame: 24 hours ]
  • The fraction (%) of the maternal dose transferred to breast milk in 24 hours [ Time Frame: 24 hours ]
Same as current
Complete list of historical versions of study NCT01309984 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study to Assess the Transfer of Fospropofol and Its Active Metabolite, Propofol, to Breast Milk Following Administration of LUSEDRA to Lactating Women Undergoing a Needed Procedure
An Open-label, Single Initial-dose, Multi-center Study to Assess the Transfer of Fospropofol and Its Active Metabolite, Propofol, to Breast Milk Following Administration of LUSEDRA to Lactating Women Undergoing a Needed Procedure
The purpose of this study is to assess the transfer of fospropofol and its active metabolite, propofol, to breast milk following administration of LUSEDRA® to lactating women undergoing a needed procedure.
E2083, or LUSEDRA® (fospropofol disodium) Injection, is an intravenous (IV) sedative-hypnotic agent indicated for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures.1 It is a water-soluble, phosphono-O-methyl prodrug of propofol. Upon IV injection, the inactive fospropofol undergoes metabolism, most notably by alkaline phosphatase enzymes, to yield the active metabolite (propofol), phosphate, and formaldehyde. Formaldehyde is quickly converted to formate in vivo, and formate is further metabolized by a folate-dependent mechanism.
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Lactating Women
  • Drug: Lusedra
    Pretreatment Phase - approximately 3 hours (Baseline) • Treatment Phase - approximately 8 days (includes Treatment, Discharge [up to 24 hours], and Follow-up Telephone Call on Day 8 post-dose after Discharge)
  • Drug: Propofol
    Pretreatment Phase - approximately 3 hours (Baseline) • Treatment Phase - approximately 8 days (includes Treatment, Discharge [up to 24 hours], and Follow-up Telephone Call on Day 8 post-dose after Discharge)
  • Active Comparator: arm 1
    Intervention: Drug: Lusedra
  • Active Comparator: arm 2
    Intervention: Drug: Propofol
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10
October 2012
October 2012   (Final data collection date for primary outcome measure)

Inclusions:

  • Lactating women undergoing a needed procedure expected to last between approximately 10 to 45 minutes
  • Subjects should be between 6 weeks and 8 months postpartum
  • Lactation must be well-established in subjects
  • Subject's infants must be full term and able to bottle-feed
  • Infants should be predominantly breast milk fed and should not receive more than one bottle of formula per day

Exclusions:

  • Subjects who are pregnant
  • Subjects undergoing a breast procedure (eg, biopsy, abscess drainage, etc.)
  • Subjects who are not willing to temporarily refrain from nursing their children during the 0-24 hour breast milk collection interval.

(Subjects may resume nursing following this interval).

Sexes Eligible for Study: Female
18 Years to 45 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01309984
E2083-A001-405
Not Provided
Not Provided
Not Provided
Eisai Inc.
Eisai Inc.
Not Provided
Study Director: Christa Nagy Eisai Inc.
Eisai Inc.
November 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP